Japan's JIC says JSR's weak financials do not affect chipmaking consolidation goal

JIC Capital, the private equity arm of Japan Investment Corp, reaffirmed its commitment to consolidating Japan's chipmaking sector through JSR, despite JSR's ¥209 billion operating loss for the year ending in March. JIC intends to pursue mergers and acquisitions to bolster JSR's semiconductor business and relist the company, with a potential timeline of five to seven years, although an earlier listing is possible. While JSR is undergoing restructuring and has replaced top management, the company is not ready to make acquisitions and has agreed to sell part of its struggling life sciences business to Tokuyama Corp for ¥82 billion.

Analysis

State-backed JIC Capital remains committed to its strategy of consolidating Japan's chipmaking sector via its portfolio company JSR, despite JSR reporting a substantial operating loss of 209 billion yen ($1.45 billion) for the year ending in March. JIC Capital's CEO, Shogo Ikeuchi, reaffirmed the goal to take JSR private, pursue industry reorganizations such as mergers, significantly grow its semiconductor business, enhance international competitiveness, and ultimately relist the company, potentially within five to seven years or earlier. To address its financial underperformance, attributed largely to its struggling life sciences division, JSR has replaced top management and is undergoing restructuring; as part of this, JSR has agreed to sell a portion of its life sciences business to Tokuyama Corp (4004) for 82 billion yen, though JSR's new CEO indicated the firm is not currently ready for further acquisitions. The JIC-led buyout and strategy have faced some industry skepticism regarding the necessity of state intervention and the inherent difficulties of executing restructuring in Japan. Resonac has expressed interest in involvement with JSR upon JIC's exit, though Ikeuchi acknowledged Resonac's debt burden as a consideration among various options. This initiative aligns with JIC's 2018 mandate to invest in companies to boost Japan's overall competitiveness.

Key Decisions for Investors

• For investors in Tokuyama Corp (4004), the 82 billion yen acquisition of JSR's life sciences unit warrants close monitoring of the integration process and the segment's contribution to earnings, especially considering the article's prompt to assess 4004 for potential undervaluation.
• The developments surrounding JSR highlight a long-term, state-backed effort to reshape Japan's semiconductor materials landscape; investors should watch for milestones in JSR's restructuring, future M&A activity in the sector, and the eventual relisting timeline as indicators of strategic progress and value realization.
• Given JSR's significant operating loss and the complexities of industry consolidation and restructuring in Japan, any investment exposure related to this initiative should acknowledge the considerable execution risks and the potentially extended timeframe for JIC's strategy to yield results.